BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Biogen, Eisai’s Alzheimer’s Candidate BAN2401 Flunks Phase II

  Another attempt at developing a treatment for Alzheimer’s has hit a wall.

  December 21, 2017

   · 

  3 min read

   · 

  Alex Keown
• 

  Deals

  The 2017 Biotech IPO Winners and Losers

  Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.

  December 21, 2017

   · 

  4 min read

   · 

  Mark Terry
• 

  Policy

  J&J Gets $30M Fine for Allegedly Restricting Access to Generic Versions of Its Pain Patch

  France’s competition authority finedJ&K $29.6M on Wednesday after it ruled the company had deliberately slowed market access to generic copies of its painkiller Durogesic.

  December 21, 2017

   · 

  1 min read
• 

  Eyenovia Eyes $35M IPO for Ocular Drug-Delivery Tech

  The company said it would use the funds to study MicroStat, a fixed combination micro-formulation product used to dilate the eyes during an eye exam.

  December 21, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  From Rags to Riches: Zynex CEO Talks About The Rise of His Leading Med Device Company

  Before founding Zynex over two decades ago, Thomas Sandgaard was a man who had just moved to the U.S. from Denmark, starting in a one-bedroom apartment, only a humble few thousand dollars to his name.

  December 21, 2017

   · 

  1 min read
• 

  Genetown

  Primary Endpoint Met in Corvia Medical’s Reduce LAP-HF I Study

  Corvia Medical said its investigational transcatheter structural heart device to treat heart failure has demonstrated success in reducing exercise pulmonary capillary wedge pressure in trial patients.

  December 21, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Celgene Crashed After Follicular Lymphoma Regimen Failed Phase III

  Celgene announced the Phase III results late Thursday and share prices dropped about 4 percent to $102.69 as of 9:30 this morning.

  December 21, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Italfarmaco R&D Head Shares Strong Clinical Data at ASH

  Italfarmaco has its eyes set on bringing a new treatment that targets the underlying mechanism of the blood disorder Polycythemia Vera.

  December 21, 2017

   · 

  3 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Google-Backed FLX Bio Scores $60M Financing

  New investors included GV and undisclosed investors.

  December 21, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Bay

  Top 5 Biotech Stocks to Buy for 2018

  A new RBC report is reasonably positive on the biotech sector for 2018 and here are some reasons why.

  December 21, 2017

   · 

  2 min read

   · 

  Mark Terry